A pharmacist may engage in collaborative drug therapy management pursuant to a collaborative practice agreement in accordance with this section. [PL 2013, c. 308, §4 (NEW).] 1. Submit to board. The pharmacist shall submit a copy of the collaborative practice agreement to the board and the licensing board that licenses the practitioner prior to the commencement of the collaborative practice. [PL 2013, c. 308, §4 (NEW).] 2. Review and revision. The signatories to a collaborative practice agreement shall establish a procedure for reviewing and, if necessary, revising the procedures and protocols of the collaborative practice agreement. [PL 2013, c. 308, §4 (NEW).] 3. Health information privacy. Services provided pursuant to a collaborative practice agreement must be performed in compliance with the federal Health Insurance Portability and Accountability Act of 1996, 42 United States Code, Section 1320d et seq. and its regulations, 45 Code of Federal Regulations, Parts 160-164. [PL 2013, c. 308, §4 (NEW).] 4. Amendments to agreement. Amendments to a collaborative practice agreement must be documented, signed and dated. [PL 2013, c. 308, §4 (NEW).] 5. Assessment; risk management. A collaborative practice agreement must include a plan for measuring and assessing patient outcomes and must include proof that liability insurance is maintained by all parties to the agreement. [PL 2013, c. 308, §4 (NEW).] 6. Contents of agreement. A practitioner and a pharmacist desiring to engage in collaborative practice in accordance with this subchapter shall execute a collaborative practice agreement that must contain, but is not limited to: A. A provision that states that activity in the initial 3 months of a collaborative practice agreement is limited to monitoring drug therapy. After the initial 3 months, the practitioner and pharmacist shall meet to review the collaborative practice agreement and determine the scope of the agreement, which may after the initial 3 months include a pharmacist's initiating, administering, monitoring, modifying and discontinuing a patient's drug therapy and reporting these actions to the practitioner in a timely manner in accordance with rules adopted pursuant to section 13846; [PL 2021, c. 271, §6 (AMD).] B. Identification and signatures of the parties to the collaborative practice agreement, the dates the agreement is signed and the beginning and ending dates of the period of time during which the agreement is in effect; [PL 2013, c. 308, §4 (NEW).] C. A provision that allows either party to cancel the collaborative practice agreement by written notification; [PL 2013, c. 308, §4 (NEW).] D. Specification of the site and setting at which the collaborative practice will occur; [PL 2013, c. 308, §4 (NEW).] E. Specification of the qualifications of the participants in the collaborative practice agreement; [PL 2013, c. 308, §4 (NEW).] F. A detailed description of the types of diseases, drugs or drug categories involved and collaborative drug therapy management allowed in each patient's case; and [PL 2013, c. 308, §4 (NEW).] G. A procedure for the referral of each patient to the practitioner. [PL 2013, c. 308, §4 (NEW).] [PL 2021, c. 271, §6 (AMD).]
‹ Prev All Maine sections Next ›
Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.